The official blog of the Lung Institute.

VIDEO: Lung Institute News Segment!

11 Feb 2014
| Under Press | Posted by

Studio 10 & the Lung Institute News Appearance

In the beginning of the Lung Institute’s most recent Studio 10 TV appearance hosts Jerome Ritchey and Roxanne Wilder took a deep breath to expand their lungs. Next, Wilder tried  breathing through a straw in an attempt to feel the struggle someone with chronic obstructive pulmonary disease (COPD) faces every day.

This attention-grabbing opening was a poignant reminder to those that might not realize how difficult it is to live each day with COPD. As the third leading cause of death in the United States, COPD is something that should be on everyone’s radar. Fortunately, the Lung Institute team is doing our best to raise awareness for COPD while informing sufferers that they do have treatment options that can improve quality of life.

Dr. James St. Louis, chief medical officer, and Jimmy. St. Louis, chief executive officer, with the Lung Institute sat down with Ritchey and Wilder to discuss how cellular therapies for COPD are offering lung disease sufferers an effective alternative to well-established treatment options.

Dr. St. Louis goes over his background with cellular therapy as well as explaining what conditions fall under the COPD umbrella—emphysema and chronic bronchitis, for those that didn’t know. Seguing off of this opening, Jimmy St. Louis proceeds to detail the Lung Institute’s cellular therapy protocol for COPD, emphysema, chronic bronchitis and pulmonary fibrosis.

What is the Treatment Process Like?

“If you’re a patient just imagine not being able to wake up in the morning and walk into the kitchen, check the mail or go on a walk with your spouse. This is what our patients are suffering from,” St. Louis said. “When they call us, they come in and we utilize an autologous process that uses their own cells, which makes it safe and effective for the patient. (There is) also a minimal chance of the cells being rejected because it’s the patients’ own cells. We then process the cells, and re-inject them back into the patient through the use of an IV. The process takes about 3 days. The patients typically comment on how easy it was for them, and certainly a lot easier than they might have expected.”

The Lung Institute is striving to get the word out about COPD prevention and cellular therapy options! Keep an eye out for more Lung Institute news segments in the future.

See the full video interview and other Lung Institute news. In the video you will find answers to the following questions:

What kind of results do you see?

Do the patients have to undergo a lifestyle change?

What kind of feedback do you get from patients?


If you or a loved one has COPD or other lung disease and want to learn more about treatment options, contact us or call 888-745-6697.


* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.